Fig. 4

The five-gene-based model can predict immunotherapy efficacy for the Imvigor210 dataset. a Kaplan–Meier analysis of the five-gene-based model. b ROC curves of TMB, NEO burden, risk score, and the combination (NEO burden, TMB and risk score). The risk score was grouped by c immunotherapy efficacy, d immune cell subgroups, and e. tumour cell subgroups. ROC receiver operating characteristic, NEO neoantigens, TMB tumour mutational burden, CR complete response, PR partial response, SD stable disease, PD progressive disease, IC immune cell, TC tumour cell